Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up (Q44712043)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Ming-Lung Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Chuan-Mo Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Chi-Ling Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Wan-Long Chuang

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sheng-Nan Lu

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Chen-Hua Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Shun-Sheng Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Li-Ying Liao

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Hsing-Tao Kuo

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

You-Chen Chao

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Shui-Yi Tung

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sien-Sing Yang

12

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Jia-Horng Kao

13

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Wei-Wen Su

14

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Chih-Lin Lin

15

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Hung-Chih Yang

16

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Pei-Jer Chen

17

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ding-Shinn Chen

18

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Chun-Jen Liu

19

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Taiwan Liver-Net Consortium

20

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

26 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

57

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

2135-2142

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Influence of chronic coinfection with hepatitis B and C virus on liver histology.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

Dual chronic hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with ?-interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

21 January 2018

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26266

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.26266

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44712043&oldid=2033414982"